# SemiLEDs Corp: financial statements, quarterly

LEDS · Nasdaq · CIK 1333822 · [Technology](/sectors/technology.md) · fiscal year ends Aug 31

Pages: [Overview](/companies/leds.md) · [Financials](/companies/leds/financials.md) · [Filings](/companies/leds/filings.md) · [Insiders](/companies/leds/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/leds/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-08-31) | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | Q4 FY2024 (2024-08-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | Q4 FY2025 (2025-08-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.5 d](/filings/0000950170-24-131245.md) | [1.7](/filings/0000950170-25-004508.md) | [0.9](/filings/0000950170-25-053013.md) | [1.3](/filings/0000950170-25-095454.md) | [1.3 d](/filings/0001193125-25-301379.md) | [1.3](/filings/0001193125-26-012226.md) | [10.9](/filings/0001193125-26-153745.md) | [17.7](/filings/0001193125-26-302451.md) | [13.2 d](/filings/0001193125-25-301379.md) | [2.6](/filings/0001193125-26-012226.md) | [1.1](/filings/0001193125-26-153745.md) | [9.1](/filings/0001193125-26-302451.md) |
| Cost of revenue | $m | [1.4 d](/filings/0000950170-24-131245.md) | [1.4](/filings/0000950170-25-004508.md) | [0.8](/filings/0000950170-25-053013.md) | [0.8](/filings/0000950170-25-095454.md) | [1.2 d](/filings/0001193125-25-301379.md) | [1.0](/filings/0001193125-26-012226.md) | [9.9](/filings/0001193125-26-153745.md) | [16.7](/filings/0001193125-26-302451.md) | [13.0 d](/filings/0001193125-25-301379.md) | [2.6](/filings/0001193125-26-012226.md) | [1.1](/filings/0001193125-26-153745.md) | [6.6](/filings/0001193125-26-302451.md) |
| Gross profit | $m | [0.0 d](/filings/0000950170-24-131245.md) | [0.2](/filings/0000950170-25-004508.md) | [0.1](/filings/0000950170-25-053013.md) | [0.5](/filings/0000950170-25-095454.md) | [0.2 d](/filings/0001193125-26-302451.md) | [0.3](/filings/0001193125-26-012226.md) | [1.0](/filings/0001193125-26-153745.md) | [0.9](/filings/0001193125-26-302451.md) | [0.2 d](/filings/0001193125-26-302451.md) | [0.0](/filings/0001193125-26-012226.md) | [0.0](/filings/0001193125-26-153745.md) | [2.5](/filings/0001193125-26-302451.md) |
| Research and development | $m | [0.3 d](/filings/0000950170-24-131245.md) | [0.4](/filings/0000950170-25-004508.md) | [0.3](/filings/0000950170-25-053013.md) | [0.3](/filings/0000950170-25-095454.md) | [0.2 d](/filings/0001193125-25-301379.md) | [0.2](/filings/0001193125-26-012226.md) | [0.3](/filings/0001193125-26-153745.md) | [0.3](/filings/0001193125-26-302451.md) | [0.4 d](/filings/0001193125-25-301379.md) | [0.4](/filings/0001193125-26-012226.md) | [0.3](/filings/0001193125-26-153745.md) | [0.4](/filings/0001193125-26-302451.md) |
| Selling, general and administrative | $m | [0.8 d](/filings/0000950170-24-131245.md) | [0.7](/filings/0000950170-25-004508.md) | [0.7](/filings/0000950170-25-053013.md) | [0.7](/filings/0000950170-25-095454.md) | [0.8 d](/filings/0001193125-25-301379.md) | [0.7](/filings/0001193125-26-012226.md) | [0.6](/filings/0001193125-26-153745.md) | [0.7](/filings/0001193125-26-302451.md) | [0.9 d](/filings/0001193125-25-301379.md) | [0.7](/filings/0001193125-26-012226.md) | [0.6](/filings/0001193125-26-153745.md) | [0.7](/filings/0001193125-26-302451.md) |
| Operating income | $m | [(1.1) d](/filings/0000950170-25-095454.md) | [(0.8)](/filings/0000950170-25-004508.md) | [(0.8)](/filings/0000950170-25-053013.md) | [(0.5)](/filings/0000950170-25-095454.md) | [(0.8) d](/filings/0001193125-26-302451.md) | [(0.7)](/filings/0001193125-26-012226.md) | [0.1](/filings/0001193125-26-153745.md) | [(0.1)](/filings/0001193125-26-302451.md) | [(1.0) d](/filings/0001193125-26-302451.md) | [(1.0)](/filings/0001193125-26-012226.md) | [(0.8)](/filings/0001193125-26-153745.md) | [1.4](/filings/0001193125-26-302451.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(0.9) d](/filings/0000950170-24-131245.md) | [(0.6)](/filings/0000950170-25-004508.md) | [(0.6)](/filings/0000950170-25-053013.md) | [(0.3)](/filings/0000950170-25-095454.md) | [(0.6) d](/filings/0001193125-25-301379.md) | [(0.5)](/filings/0000950170-25-004508.md) | [0.4](/filings/0000950170-25-053013.md) | [0.2](/filings/0000950170-25-095454.md) | [(1.2) d](/filings/0001193125-25-301379.md) | [(0.7)](/filings/0001193125-26-302451.md) | [(0.6)](/filings/0001193125-26-302451.md) | [1.5](/filings/0001193125-26-302451.md) |
| Diluted EPS | $ per share | not reported | [(0.12)](/filings/0000950170-25-004508.md) | [(0.11)](/filings/0000950170-25-053013.md) | [(0.04)](/filings/0000950170-25-095454.md) | not reported | [(0.08)](/filings/0001193125-26-012226.md) | [0.05](/filings/0001193125-26-153745.md) | [0.03](/filings/0001193125-26-302451.md) | not reported | [(0.09)](/filings/0001193125-26-012226.md) | [(0.07)](/filings/0001193125-26-153745.md) | [0.18](/filings/0001193125-26-302451.md) |
| Basic EPS | $ per share | not reported | [(0.12)](/filings/0000950170-25-004508.md) | [(0.11)](/filings/0000950170-25-053013.md) | [(0.04)](/filings/0000950170-25-095454.md) | not reported | [(0.08)](/filings/0001193125-26-012226.md) | [0.05](/filings/0001193125-26-153745.md) | [0.03](/filings/0001193125-26-302451.md) | not reported | [(0.09)](/filings/0001193125-26-012226.md) | [(0.07)](/filings/0001193125-26-153745.md) | [0.18](/filings/0001193125-26-302451.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-08-31) | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | FY2024 (2024-08-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | FY2025 (2025-08-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [2.6](/filings/0000950170-24-131245.md) | [2.3](/filings/0000950170-25-004508.md) | [1.6](/filings/0000950170-25-053013.md) | [1.7](/filings/0000950170-25-095454.md) | [1.7](/filings/0001193125-25-301379.md) | [1.2](/filings/0001193125-26-012226.md) | [2.4](/filings/0001193125-26-153745.md) | [2.4](/filings/0001193125-26-302451.md) | [2.6](/filings/0001193125-26-302451.md) | [2.9](/filings/0001193125-26-012226.md) | [4.0](/filings/0001193125-26-153745.md) | [6.0](/filings/0001193125-26-302451.md) |
| Current assets | $m | [7.6](/filings/0000950170-24-131245.md) | [7.3](/filings/0000950170-24-004103.md) | [6.4](/filings/0000950170-24-043853.md) | [6.4](/filings/0000950170-24-082869.md) | [5.9](/filings/0001193125-25-301379.md) | [5.5](/filings/0000950170-25-004508.md) | [18.2](/filings/0000950170-25-053013.md) | [17.7](/filings/0000950170-25-095454.md) | [11.3](/filings/0001193125-26-302451.md) | [10.2](/filings/0001193125-26-012226.md) | [12.4](/filings/0001193125-26-153745.md) | [13.9](/filings/0001193125-26-302451.md) |
| Total assets | $m | [13.5](/filings/0000950170-24-131245.md) | [13.2](/filings/0000950170-24-004103.md) | [12.0](/filings/0000950170-24-043853.md) | [11.5](/filings/0000950170-24-082869.md) | [11.1](/filings/0001193125-25-301379.md) | [10.4](/filings/0000950170-25-004508.md) | [23.2](/filings/0000950170-25-053013.md) | [23.2](/filings/0000950170-25-095454.md) | [15.6](/filings/0001193125-26-302451.md) | [14.2](/filings/0001193125-26-012226.md) | [16.3](/filings/0001193125-26-153745.md) | [17.5](/filings/0001193125-26-302451.md) |
| Current liabilities | $m | [9.7](/filings/0000950170-24-131245.md) | [9.9](/filings/0000950170-24-004103.md) | [6.6](/filings/0000950170-24-043853.md) | [6.8](/filings/0000950170-24-082869.md) | [7.0](/filings/0001193125-25-301379.md) | [7.1](/filings/0000950170-25-004508.md) | [18.0](/filings/0000950170-25-053013.md) | [17.6](/filings/0000950170-25-095454.md) | [11.4](/filings/0001193125-26-302451.md) | [10.9](/filings/0001193125-26-012226.md) | [13.6](/filings/0001193125-26-153745.md) | [13.5](/filings/0001193125-26-302451.md) |
| Total liabilities | $m | [12.3](/filings/0000950170-24-131245.md) | [12.4](/filings/0000950170-24-004103.md) | [8.9](/filings/0000950170-24-043853.md) | [8.7](/filings/0000950170-24-082869.md) | [8.9](/filings/0001193125-25-301379.md) | [8.8](/filings/0000950170-25-004508.md) | [19.6](/filings/0000950170-25-053013.md) | [19.2](/filings/0000950170-25-095454.md) | [12.8](/filings/0001193125-26-302451.md) | [12.2](/filings/0001193125-26-012226.md) | [14.8](/filings/0001193125-26-153745.md) | [14.5](/filings/0001193125-26-302451.md) |
| Long-term debt | $m | [1.3](/filings/0000950170-24-131245.md) | [1.2](/filings/0000950170-24-004103.md) | [1.1](/filings/0000950170-24-043853.md) | [1.0](/filings/0000950170-24-082869.md) | [0.9](/filings/0001193125-25-301379.md) | [0.7](/filings/0000950170-25-004508.md) | [0.6](/filings/0000950170-25-053013.md) | [0.6](/filings/0000950170-25-095454.md) | [0.4](/filings/0001193125-26-302451.md) | [0.3](/filings/0001193125-26-012226.md) | [0.2](/filings/0001193125-26-153745.md) | [0.1](/filings/0001193125-26-302451.md) |
| Current portion of debt | $m | [5.0](/filings/0000950170-24-131245.md) | [5.1](/filings/0000950170-24-004103.md) | [2.9](/filings/0000950170-24-043853.md) | [2.8](/filings/0000950170-24-082869.md) | [2.9](/filings/0001193125-25-301379.md) | [2.8](/filings/0000950170-25-004508.md) | [1.2](/filings/0000950170-25-053013.md) | [1.3](/filings/0000950170-25-095454.md) | [1.3](/filings/0001193125-26-302451.md) | [1.3](/filings/0001193125-26-012226.md) | [1.3](/filings/0001193125-26-153745.md) | [1.3](/filings/0001193125-26-302451.md) |
| Shareholders' equity | $m | [1.2](/filings/0000950170-24-131245.md) | [0.7](/filings/0000950170-24-004103.md) | [3.0](/filings/0000950170-24-043853.md) | [2.7](/filings/0000950170-24-082869.md) | [2.2](/filings/0001193125-25-301379.md) | [1.6](/filings/0000950170-25-004508.md) | [3.6](/filings/0000950170-25-053013.md) | [4.0](/filings/0000950170-25-095454.md) | [2.8](/filings/0001193125-26-302451.md) | [2.1](/filings/0001193125-26-012226.md) | [1.5](/filings/0001193125-26-153745.md) | [3.1](/filings/0001193125-26-302451.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-08-31) | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | Q4 FY2024 (2024-08-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | Q4 FY2025 (2025-08-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(339) d](/filings/0000950170-25-095454.md) | [(79.0)](/filings/0000950170-25-004508.md) | [(600) d](/filings/0000950170-25-053013.md) | [109 d](/filings/0000950170-25-095454.md) | [209 d](/filings/0001193125-26-302451.md) | [(158)](/filings/0001193125-26-012226.md) | [1,405 d](/filings/0001193125-26-153745.md) | [693 d](/filings/0001193125-26-302451.md) | [260 d](/filings/0001193125-26-302451.md) | [361](/filings/0001193125-26-012226.md) | [1,203 d](/filings/0001193125-26-153745.md) | [2,197 d](/filings/0001193125-26-302451.md) |
| Capital expenditure | $k | [(12.0) d](/filings/0000950170-24-131245.md) | [50.0](/filings/0000950170-25-004508.md) | [19.0 d](/filings/0000950170-25-053013.md) | [11.0 d](/filings/0000950170-25-095454.md) | [43.0 d](/filings/0001193125-25-301379.md) | [118](/filings/0001193125-26-012226.md) | [120 d](/filings/0001193125-26-153745.md) | [310 d](/filings/0001193125-26-302451.md) | [21.0 d](/filings/0001193125-25-301379.md) | [30.0](/filings/0001193125-26-012226.md) | [14.0 d](/filings/0001193125-26-153745.md) | [87.0 d](/filings/0001193125-26-302451.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2022-11-30) | Q2 FY2023 (2023-02-28) | Q3 FY2023 (2023-05-31) | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [4,836](/filings/0000950170-24-004103.md) | [4,866](/filings/0000950170-24-043853.md) | [4,897](/filings/0000950170-24-082869.md) | [4,885](/filings/0000950170-25-004508.md) | [4,905](/filings/0000950170-25-053013.md) | [7,185](/filings/0000950170-25-095454.md) | [7,212](/filings/0001193125-26-012226.md) | [7,222](/filings/0001193125-26-153745.md) | [7,232](/filings/0001193125-26-302451.md) | [8,226](/filings/0001193125-26-012226.md) | [8,255](/filings/0001193125-26-153745.md) | [8,264](/filings/0001193125-26-302451.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 8,273,403 at 2026-07-07, from the cover of the [10-Q filed 2026-07-14](/filings/0001193125-26-302451.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.